Comparison · NCT04112316-c10edc77
Liothyronine (LT3) vs Placebo: T3 Level
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Liothyronine (LT3) vs Placebo: T3 Level. Trial comparisons, record NCT04112316-c10edc77. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04112316-c10edc77
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.154 | 0.0615 | 0.335 | wilson | |
| Risk in group 2 | 0 | 0 | 0.129 | wilson | |
| Risk difference, group 1 minus group 2 | 0.154 | -0.00458 | 0.335 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one more participant with the outcome on Liothyronine (LT3) than on Placebo | 6.5 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Liothyronine (LT3) | Participants who received liothyronine for the first 8 weeks or the last 8 weeks of the study. | 4 | 26 | OG000 |
| Group 2 | Placebo | Participants who received placebo for the first 8 weeks or the last 8 weeks of the study. | 0 | 26 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- T3 Level
- Description
- Number of participants with T3 levels above upper limit of reference range
- Time frame
- 8 weeks
- Population
Source ClinicalTrials.gov
Trial
- Title
- Developing Oral LT3 Therapy for Heart Failure - HFrEF
- NCT number
- NCT04112316
- Phases
- PHASE1, PHASE2
- Conditions
- Heart Failure With Reduced Ejection Fraction (HFrEF), Low T3 Syndrome
- Interventions
- Liothyronine, Placebo
- Lead sponsor
- University of Pennsylvania
- Results first posted
- 2024-12-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04112316?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04112316-c10edc77